Pipeline
SHX-020: An oral tablet of heparin, which demonstrates a comparable PK (anti-Xa activity) with injectables of heparin in large animals. The nonclinical and clinical path has been discussed and agreements were reached with FDA. The oral administration of heparin may potentially transform the applications of heparin in many indication areas.
SHX-021：An oral tablet of semaglutide, currently in IND enabling stage. It has demonstrated 3~5 folds higher oral bioavailability in beagle dog model with reduced variability, enabling the development of weekly dosing. The Monkey PK and pre-Tox also support the weekly dosing design. The formulation also has a very nice performance on stability at 3 months under the accelerated condition. A few PCT patents have been filed and entered into different nations to protect the product.
SHX-022：An oral tablet of fixed dose combination of semaglutide and SGLT2i, which demonstrates comparable PK of semaglutide or SGLT2i with its standalone semaglutide formulation or commercial SGLT2i product, respectively.
SHX-024: An oral tablet of a GLP-1/GIP co-agonist peptide. The initial oral formulation indicated a commercially viable tablet size/cost.